Hide Board Information

Show Board Information

First National Community Bancorp Inc FNCB

Board Mod: Add me as mod

Asst Mods:

Last Post: 11/06/2023 10:34:28 PM

Board Marks: 0

Posts Today: 0

Board Views Today: 7

First National Community Bancorp Inc (OTCMRKTS: FNCB) Stock Message Board

1. FNCB Company Profile

    

2. FNCB Time & Sales

    

3. FNCB Recent News

    

4. FNCB Filings

    

5. FNCB Financials

    

6. FNCB Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

5	$FNCB News Article - SHAREHOLDER INVESTIGATION:	whytestocks	11/04/2023 8:20:45 AM
4	FNCB Financials 07/16/2014 11:31:30 First	Emylers	07/16/2014 12:31:26 PM
3	Latest First National Community Bancorp Inc	Stock_Tracker	03/09/2014 9:15:34 PM
2	FNCB 6.35 Stock Charts $FNCB 1 Month Chart	chartguy89	03/07/2014 7:11:29 AM
1	FNCB Stock Charts Last: -0.20 Wednesday, February	chartguy89	02/26/2014 5:42:25 AM

Newer

Recent Articles

• Purpose Investments Reveals Distributions for Funds in 2025
• JLL Income Property Trust Expands Footprint with New Acquisition
• Innovative Trade Bridge by Canton Fair Enhances Global Commerce
• CARsgen Reports Promising Long-term Findings for Zevor-cel Use
• ACM Research Introduces Advanced Technology for Gold Etching
• Legal Action Initiated Against RxSight for Misleading Claims
• LifeMD Faces Class Action Lawsuit Over Irregularities
• Southwest Gas Holdings Announces Exciting Dividend Plans
• Marketing Maven Earns Prestigious Top 10 Ranking in 2024
• NAVER CEO Joins UN Global Compact Board to Foster AI Governance
• Nuix Secures Major Contract with German Tax Authority
• How Investing $1000 in Lowe's Today Translates to Growth
• Nuix Secures Multi-Year Agreement with German Tax Authority
• Astounding Returns: $1000 Investment in Deckers Outdoor Today
• Ascletis Reveals Promising Results for Acne Treatment FASN Inhibitor
• Netskope Sets Share Price for Upcoming IPO Event
• Nuix Secures Landmark Deal with German Tax Authority
• Noble Panacea Launches Innovative Night Serum Celebrating Transformation
• ChowChow Cloud Celebrates Successful Initial Public Offering
• Discover the Long-Term Growth of Your Investment in Adobe
• Nabors Energy Transition Corp. II Extends Business Combo Deadline
• MIDAS and OLEON Collaborate for Eco-Friendly Data Center Cooling
• Streamex Corp. Partners with Simplify to Innovate ETF Solutions
• Revitalizing Chinese Tech Stocks Amid Evolving Trade Talks
• Transforming a $100 Investment in Commercial Metals Over a Decade
• Disney Faces Investigation Over Children's Data Privacy Issues
• Investors Seize Opportunity: Join Novo Nordisk Securities Case Now
• Micron Technology: A Journey of Investment Growth Over 20 Years
• MIDAS and OLEON Collaborate for Eco-Friendly Data Center Solutions
• Investor Opportunities: Join the Easterly ROCMuni Class Action
• Embark on a Unique Winter Experience with Vermejo's Sabbatical
• Investigating RCI Hospitality Holdings for Shareholder Rights
• New Leadership at River Valley Community Bancorp: Sinclair Joins Board
• Transforming a $100 Investment in Barrick Mining Over Years
• Understanding the Long-Term Growth of Costco Investments
• Investors Alert: Alto Neuroscience, Inc. Class Action Case Overview
• ECD Automotive Design Announces Correction for CUSIP Number
• River Valley Community Bancorp Welcomes New Board Member Robert Sinclair
• Birmingham's Hispanic Heritage Festival Brings Joy and Unity
• Woodward, Inc. Declares Cash Dividend for Stockholders
• GoldHaven Resources Engages in Private Placement Offering
• Investors Urged to Contact Attorneys Over RxSight Class Action
• Investor Alert: Legal Claims for Simulations Plus, Inc. Stockholders
• MetLife's Remarkable Gains: An Investment Journey Revealed
• GoldHaven Resources Initiates Exciting Equity Financing
• Understanding the P/E Ratio Implications for Investors
• Bullish Reports Impressive Second Quarter Revenue Growth
• Westlawn Americas Offshore Expands with Strategic Acquisition
• Ontario International Airport Achieves Top Satisfaction Ranking
• Mounjaro's Promising Phase 3 Trial Results in Young Patients